TITLE:
Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)

CONDITION:
Amyotrophic Lateral Sclerosis

INTERVENTION:
TCH346

SUMMARY:

      This is a global multicenter study designed to evaluate the safety and clinical effects of 4
      oral doses of TCH346 (1.0, 2.5, 7.5, and 15 mg) compared to placebo in patients with mild or
      mild to moderate stages of ALS. The study consists of 3 phases: screening (up to 2 weeks),
      run-in (16 weeks), and a double-blind treatment phase of variable duration (at least 24
      weeks).
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 21 Years to 80 Years
Criteria:

        Inclusion criteria:

          -  clinical diagnosis of laboratory-supported probable, probable, or definite ALS;

          -  sporadic or familial ALS;

          -  ALS symptom onset for no more than 3 yrs at study entry;

          -  FVC equal to or more than 70%;

          -  patients who are either riluzole naive or patients who are receiving concomitant
             treatment with riluzole at a stable dose of riluzole (50 mg bid) at study start.

        Exclusion criteria:

          -  Known or suspected chronic infectious disease including HIV, hepatitis B, or
             hepatitis C.

          -  Clinically significant ECG abnormalities.

          -  Known hypersensitivity to study drug or related drugs (e.g. selegiline, MAO-A and B
             inhibitors, or tricyclic antidepressants).

          -  Patients treated with potent inhibitors of CYP1A2 or CYP3A4 (a list of such
             inhibitors will be provided to the investigator).

          -  Treatment with MAO-A and B inhibitors (including selegiline) within the past 30 days.
      
